Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00074742" target="_blank" >RIV/00159816:_____/21:00074742 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/21:00122152

Výsledek na webu

<a href="https://link.springer.com/article/10.1007%2Fs10238-021-00702-2" target="_blank" >https://link.springer.com/article/10.1007%2Fs10238-021-00702-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10238-021-00702-2" target="_blank" >10.1007/s10238-021-00702-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis

Popis výsledku v původním jazyce

Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are endowed with the ability of establishing lifelong latency in human hosts and reactivating in immunocompromised subjects, including patients suffering from ulcerative colitis (UC). We, therefore, aimed to investigate virus-specific immunity in UC patients. A cohort of 24 UC patients (14 responders and 10 refractory to therapy) and 26 control subjects was prospectively enrolled to undergo virus-specific serology (by ELISA assay) and assessment of both CD4(+) and CD8(+) virus-specific T-cell response (by interferon-gamma enzyme-linked immunospotanalysis). In parallel, mucosal viral load was determined by quantitative real-time PCR and the values were correlated with both clinical and endoscopic indexes of activity. For statistics, the t-test, Mann-Withney test, Fisher&apos;s exact test and Spearman rank correlation test were applied; p &lt; 0.05 was considered significant. EBV-specific CD4(+) and CD8(+) T-cell responses were significantly lower in UC patients compared to controls (p &lt; 0.0001 and p = 0.0006, respectively), whereas no difference was found for HCMV-specific T-cell response. When dividing the UC group according to response to therapy, both responders and refractory UC patients showed a deficient EBV-specific CD4(+) T-cell response with respect to controls (p &lt; 0.04 and p = 0.0003, respectively). Moreover, both EBV and HCMV mucosal loads were significantly higher in refractory UC than in responders and controls (p = 0.007 and 0.003; and p = 0.02 and 0.001, respectively), and correlated with activity indexes. Steroid therapy seemed the main risk factor for triggering EBV colitis. Finally, no cases of IgM positivity were found in the study population. An impaired EBV-specific immunity was clearly evident in UC patients, mostly in those refractory to therapy. The ELISPOT assay may serve as new tool for quantifying and monitoring virus-specific T-cell immunity in UC.

Název v anglickém jazyce

Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis

Popis výsledku anglicky

Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are endowed with the ability of establishing lifelong latency in human hosts and reactivating in immunocompromised subjects, including patients suffering from ulcerative colitis (UC). We, therefore, aimed to investigate virus-specific immunity in UC patients. A cohort of 24 UC patients (14 responders and 10 refractory to therapy) and 26 control subjects was prospectively enrolled to undergo virus-specific serology (by ELISA assay) and assessment of both CD4(+) and CD8(+) virus-specific T-cell response (by interferon-gamma enzyme-linked immunospotanalysis). In parallel, mucosal viral load was determined by quantitative real-time PCR and the values were correlated with both clinical and endoscopic indexes of activity. For statistics, the t-test, Mann-Withney test, Fisher&apos;s exact test and Spearman rank correlation test were applied; p &lt; 0.05 was considered significant. EBV-specific CD4(+) and CD8(+) T-cell responses were significantly lower in UC patients compared to controls (p &lt; 0.0001 and p = 0.0006, respectively), whereas no difference was found for HCMV-specific T-cell response. When dividing the UC group according to response to therapy, both responders and refractory UC patients showed a deficient EBV-specific CD4(+) T-cell response with respect to controls (p &lt; 0.04 and p = 0.0003, respectively). Moreover, both EBV and HCMV mucosal loads were significantly higher in refractory UC than in responders and controls (p = 0.007 and 0.003; and p = 0.02 and 0.001, respectively), and correlated with activity indexes. Steroid therapy seemed the main risk factor for triggering EBV colitis. Finally, no cases of IgM positivity were found in the study population. An impaired EBV-specific immunity was clearly evident in UC patients, mostly in those refractory to therapy. The ELISPOT assay may serve as new tool for quantifying and monitoring virus-specific T-cell immunity in UC.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30200 - Clinical medicine

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and Experimental Medicine

ISSN

1591-8890

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

379-388

Kód UT WoS článku

000633271600001

EID výsledku v databázi Scopus

—